Back to Search Start Over

Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.

Authors :
Royston L
Papanicolaou GA
Neofytos D
Source :
Viruses [Viruses] 2024 Jul 05; Vol. 16 (7). Date of Electronic Publication: 2024 Jul 05.
Publication Year :
2024

Abstract

Despite the significant progress made, CMV infection is one of the most frequent infectious complications in transplant recipients. CMV infections that become refractory or resistant (R/R) to the available antiviral drugs constitute a clinical challenge and are associated with increased morbidity and mortality. Novel anti-CMV therapies have been recently developed and introduced in clinical practice, which may improve the treatment of these infections. In this review, we summarize the treatment options for R/R CMV infections in adult hematopoietic cell transplant and solid organ transplant recipients, with a special focus on newly available antiviral agents with anti-CMV activity, including maribavir and letermovir.

Details

Language :
English
ISSN :
1999-4915
Volume :
16
Issue :
7
Database :
MEDLINE
Journal :
Viruses
Publication Type :
Academic Journal
Accession number :
39066247
Full Text :
https://doi.org/10.3390/v16071085